SYDNEY (XFN-ASIA) - Biota Holdings Ltd said it has entered into a worldwide research collaboration and licensing agreement with Germany's Boehringer Ingelheim to develop and commercialize Biota's nucleoside analogues product designed to treat Hepatitis C virus infections and potentially other diseases.
Under the terms of the agreement, Biota is eligible to receive payments of up to 102 mln usd based on products achieving certain clinical, regulatory and commercialization milestones.
The payments include an initial technology access fee and research support.
Biota said it will also receive royalties on future sales of licensed products marketed by Boehringer Ingelheim.
Specific terms of the agreement were not disclosed.
bruce.hextall@xfn.com
blh/mas